Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 12/20 | 0.70 |
| ▸ | ADORA3 | P0DMS8 | 5/20 | 0.52 |
| ▸ | ADORA2B | P29275 | 4/20 | 0.52 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.52 |
| ▸ | NT5E | P21589 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6337865 | 1.00 | ADORA2A (0.70) | ADORA2AADORA3ADORA2BADORA1NT5E | |
| SCHEMBL5695185 | 0.94 | ADORA2A (0.71) | ADORA2AADORA3ADORA2BADORA1NT5E | |
| SCHEMBL5695190 | 0.94 | ADORA2A (0.71) | ADORA2AADORA3ADORA2BADORA1NT5E | |
| SCHEMBL724653 | 0.93 | ADORA2A (0.61) | ADORA2AADORA3ADORA2BADORA1 | |
| SCHEMBL6917842 | 0.93 | ADORA2A (0.61) | ADORA2AADORA3ADORA2BADORA1 | |
| SCHEMBL6917844 | 0.93 | ADORA2A (0.61) | ADORA2AADORA3ADORA2BADORA1 | |
| SCHEMBL724654 | 0.93 | ADORA2A (0.61) | ADORA2AADORA3ADORA2BADORA1 | |
| SCHEMBL5694974 | 0.92 | ADORA2A (0.69) | ADORA2AADORA3ADORA2BADORA1NT5E | |
| SCHEMBL5694980 | 0.92 | ADORA2A (0.69) | ADORA2AADORA3ADORA2BADORA1NT5E | |
| SCHEMBL5695192 | 0.92 | ADORA2A (0.70) | ADORA2AADORA3ADORA2BADORA1NT5E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050250730-A1 | Combination of an adenosine A2A-receptor agonist and tiotropium or a derivative thereof for treating obstructive airways and other inflammatory diseases | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2005-11-10 | — | — | US | claimed |
| US-20050209185-A1 | Combination of an adenosine A2A-receptor agonist and tiotropium or a derivative thereof for treating obstructive airways and other inflammatory diseases | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2005-09-22 | — | — | US | claimed |
| US-20030013675-A1 | Combination of an adenosine A2A-receptor agonist and tiotropium or a derivative thereof for treating obstructive airways and other inflammatory diseases | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-01-16 | — | — | US | claimed |
| EP-1121372-B1 | ADENINE DERIVATIVES | PFIZER LTD (GB) | 2006-06-28 | — | — | EP | disclosed |
| US-20050250730-A1 | Combination of an adenosine A2A-receptor agonist and tiotropium or a derivative thereof for treating obstructive airways and other inflammatory diseases | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2005-11-10 | — | — | US | disclosed |
| US-20050209185-A1 | Combination of an adenosine A2A-receptor agonist and tiotropium or a derivative thereof for treating obstructive airways and other inflammatory diseases | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2005-09-22 | — | — | US | disclosed |
| US-20030013675-A1 | Combination of an adenosine A2A-receptor agonist and tiotropium or a derivative thereof for treating obstructive airways and other inflammatory diseases | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-01-16 | — | — | US | disclosed |
| WO-2002067909-A1 | NEW METHOD OF BRONCHODILATORY THERAPY | GLAXO GROUP LIMITED (GB) | 2002-09-06 | — | — | WO | disclosed |
| US-6326359-B1 | PURINE DERIVATIVES | PFIZER INC | 2001-12-04 | — | — | US | disclosed |
| EP-1121372-A1 | ADENINE DERIVATIVES | Pfizer Limited (GB) | 2001-08-08 | — | — | EP | disclosed |
| WO-2000023457-A1 | ADENINE DERIVATIVES | PFIZER LIMITED (GB) | 2000-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050209185-A1 | Combination of an adenosine A2A-receptor agonist and tiotropium or a derivative thereof for treating obstructive airways and other inflammatory diseases | ADORA2A, ADORA3, ADORA2B | ADORA2A 1/4885ADORA3 2/4885ADORA2B 3/4885 |
| US-20030013675-A1 | Combination of an adenosine A2A-receptor agonist and tiotropium or a derivative thereof for treating obstructive airways and other inflammatory diseases | ADORA2A, ADORA3, ADORA2B | ADORA2A 1/4885ADORA3 2/4885ADORA2B 3/4885 |
| US-20050250730-A1 | Combination of an adenosine A2A-receptor agonist and tiotropium or a derivative thereof for treating obstructive airways and other inflammatory diseases | ADORA2A, ADORA3, ADORA2B | ADORA2A 1/4885ADORA3 2/4885ADORA2B 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.